-

Medable to Present at Jefferies Global Healthcare Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading evidence-generation platform provider for modern clinical trials, today announced that Medable Co-founder and CEO Michelle Longmire will present at the Jefferies Global Healthcare Conference. The live presentation will take place on Thursday, June 6, 2024, at 3:30p.m. ET in New York City, New York.

The Management Team will also be available for 1:1 investor meetings at the conference. Please reach out to your Jefferies representative to schedule.

For more information, please contact:
Burak Over
SVP, Corporate Development & Investor Relations
burak@medable.com

To learn more about Medable, visit medable.com.

About Medable

Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Named a Leader in the industry by Everest Group and awarded Best Digital Health Solution by the Galien Foundation, the Medable platform has been deployed in more than 300 trials in 60 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and ranked #398 on the Inc. 5000 in 2023.

Contacts

Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Industry:

Medable Inc.

Details
Headquarters: Palo Alto, California
CEO: Michelle Longmire
Employees: 350
Organization: PRI
Release Versions
English

Contacts

Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Social Media Profiles
Medable on LinkedIn
More News From Medable Inc.

Medable Introduces AI Agent to Reduce Burden at Research Sites By Assisting Principal Investigators with Oversight of eCOA Data

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for AI-powered clinical development, today launched Agentic AI for research sites to reduce burden and assist principal investigators (PIs) in oversight and monitoring of electronic clinical outcome assessment (eCOA) data. Medable’s newest agent integrates seamlessly within its eCOA system workflows. Released just after Medable’s TMF and CRA agents, its PI Summary Agent continues the company’s rapid rollout of fun...

Medable Debuts AI Agent for Automating Trial Master File (TMF) Processes

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for AI-powered clinical development, today announced its TMF Agent, which brings artificial intelligence and automation to the labor-intensive processes required for trial document management. TMF Agent significantly improves quality and consistency while drastically reducing the manual effort in document management. It is built on Medable’s Agent Studio, the industry’s first agentic AI platform for clinical devel...

Medable Launches Innovation Evidence Workshop – First Collaboration To Bring Leaders Together on DCT Impact, Adoption, and Best Practices

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable, the leading provider of AI-powered clinical trial technology, today announced its Innovation Evidence Workshop series, developed in collaboration with and facilitated by the Tufts Center for the Study of Drug Development (Tufts CSDD). Leaders from 20 pharmaceutical, biotech, and contract research organizations (CROs) participated in the inaugural invitation-only workshop held on November 19 in Boston, MA. Programming featured representatives from the...
Back to Newsroom